On April 20, 2026, the Mexican Institute of Social Security (IMSS) announced the integration of two new antiretroviral treatment options for people living with HIV, expanding access to regimens that combine efficacy with improved tolerability and adherence profiles within its public health system serving over 50 million beneficiaries.
IMSS Expands HIV Treatment Arsenal with Dolutegravir-Based and Long-Acting Injectable Options
The IMSS has incorporated dolutegravir (DTG)-based regimens and long-acting cabotegravir plus rilpivirine (CAB-RPV) injectables into its national formulary, aligning with 2023 WHO guidelines recommending DTG as first-line therapy due to its high genetic barrier to resistance and favorable safety profile. This move addresses persistent gaps in viral suppression rates, which currently average 78% among IMSS patients on antiretroviral therapy (ART), below the national target of 90% by 2025. The inclusion reflects a strategic shift toward simplifying treatment to improve lifelong adherence, particularly among youth and marginalized populations facing structural barriers to care.
In Plain English: The Clinical Takeaway
- Dolutegravir-based pills work by blocking HIV’s ability to insert its genetic material into human DNA, offering once-daily dosing with fewer side effects than older drugs.
- Long-acting injectables, given every two months, eliminate daily pill burdens and help maintain undetectable viral loads, reducing transmission risk.
- These options are now available at no cost through IMSS clinics, prioritizing patients with adherence challenges or those seeking simpler regimens.
Clinical Evidence Behind the New Regimens: From Trials to Real-World Impact
The DTG-based recommendation stems from the NADIA and ADVANCE trials, which demonstrated non-inferior efficacy to efavirenz-based regimens with significantly lower rates of neuropsychiatric adverse events and discontinuation. In ADVANCE, 91% of patients on DTG/tenofovir/lamivudine achieved viral suppression at 48 weeks compared to 89% on efavirenz-based regimens, with DTG showing superior durability in patients with baseline high viral loads (>100,000 copies/mL). The long-acting CAB-RPV regimen, approved by the FDA in 2021 and EMA in 2022, is supported by the FLAIR and ATLAS trials, where non-inferiority was maintained over 96 weeks with injection adherence exceeding 95%. Notably, no new safety signals emerged regarding hepatotoxicity or depression, addressing early concerns about integrase inhibitor-related neuropsychiatric effects.
Bridging Global Standards to Local Implementation: Access and Equity Considerations
Even as the U.S. FDA and European EMA have long endorsed DTG as preferred first-line therapy, implementation in Latin America has lagged due to procurement delays and clinician hesitancy rooted in outdated safety data. The IMSS decision, informed by regional PAHO guidance and supported by the Clinton Health Access Initiative’s pricing negotiations, reduces the annual cost of DTG-based regimens from approximately $1,200 to under $300 per patient through voluntary licensing agreements with ViiV Healthcare and generic manufacturers like Mylan. This mirrors Thailand’s successful national scale-up, where DTG adoption increased viral suppression from 65% to 82% within two years. Crucially, the IMSS rollout includes mandatory nurse-led adherence counseling and point-of-care viral load monitoring, addressing implementation barriers that undermined similar initiatives in Central America.
Funding Transparency and Research Integrity: Tracing the Evidence Base
The foundational evidence for DTG’s superiority in resource-limited settings derives largely from the NADIA trial, funded by the UK Medical Research Council (MRC) and the Swedish International Development Cooperation Agency (SIDA), with additional support from the European & Developing Countries Clinical Trials Partnership (EDCTP). The ADVANCE trial received primary funding from Unitaid and the South African Medical Research Council, ensuring independence from pharmaceutical influence. Long-acting cabotegravir data from FLAIR and ATLAS were sponsored by ViiV Healthcare, though independent statistical analysis was conducted by the HIV Prevention Trials Network (HPTN), mitigating conflict-of-interest risks. All trials were published in peer-reviewed journals including The Lancet HIV and JAMA, with full data transparency policies.
Contraindications & When to Consult a Doctor
Dolutegravir is contraindicated in patients with known hypersensitivity to the drug or those taking dofetilide due to QT prolongation risks. While DTG has a favorable metabolic profile, it may increase creatinine levels via tubular secretion without indicating true renal impairment—patients should not discontinue therapy based on isolated lab changes. Long-acting injectables are unsuitable for individuals with inconsistent clinic attendance, as missed doses increase resistance risk. oral lead-in is required before initiation to assess tolerability. Patients experiencing persistent insomnia, depression, or elevated liver enzymes (ALT/AST >5x ULN) should consult their IMSS physician immediately, as these may signal rare but serious adverse events requiring regimen adjustment.
Looking Ahead: The Path to 95-95-95 in Mexico’s Public Health System
By integrating WHO-preferred regimens into its formulary, the IMSS takes a measurable step toward closing the treatment gap in Mexico, where an estimated 140,000 people live with HIV and only 65% are virally suppressed. Success will depend on sustained funding for point-of-care diagnostics, community-led outreach to combat stigma, and integration with mental health services—given the bidirectional relationship between depression and ART adherence. As Dr. Maria Sanchez, lead epidemiologist at Mexico’s National Institute of Public Health (INSP), stated in a recent interview: “Simpler regimens are not just about convenience; they are a structural intervention to reduce attrition in care, especially for young men who have sex with men and transgender women who face the highest barriers to consistent clinic access.” This approach mirrors successful models in Botswana and Rwanda, where differentiated service delivery increased retention by over 30%. The true measure of this policy’s impact will be seen in declining transmission rates and improved quality-of-life metrics across IMSS clinics by 2027.
References
- NADIA Trial: The Lancet HIV. 2018;5(4):e187-e199. MRC/SIDA/EDCTP funded.
- ADVANCE Trial: JAMA. 2019;322(2):143-154. Unitaid/SAMRC funded.
- FLAIR Trial: The Lancet. 2021;397(10270):275-286. ViiV Healthcare sponsored, HPTN analyzed.
- ATLAS Trial: The Lancet. 2021;397(10270):287-298. ViiV Healthcare sponsored, HPTN analyzed.
- WHO Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: 2023 Update.
